Physician profile
Gary E Miller
NPI 1770503336
$2,947.24
in general payments reported to CMS, 2019-2025
21 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $466 · 2021: $653 · 2022: $291 · 2023: $299 · 2024: $832 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $703.38 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $397.96 | 2020-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $337.38 | 2023-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $170.39 | 2020-2025 | Invega Trinza, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $164.73 | 2019-2024 | Fanapt, Hetlioz |
| Abbvie INC. | $161.37 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.49 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $141.27 | 2021 | |
| Lundbeck LLC | $138.38 | 2024 | Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $89.60 | 2024-2025 | Cobenfy |
| Corium, LLC | $88.13 | 2021-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $74.84 | 2024-2025 | Ingrezza |
| Eisai INC. | $73.23 | 2020 | |
| Jazz Pharmaceuticals INC. | $59.24 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $45.97 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $38.83 | 2020-2024 | Aristada, Lybalvi |
| Adlon Therapeutics L.P. | $35.57 | 2020 | |
| Almatica Pharma LLC | $26.49 | 2023 | Loreev Xr |
| Allergan, INC. | $20.55 | 2020 | |
| Dentsply Sirona INC | $19.94 | 2025 | X-Smart |
| Neuronetics, INC. | $4.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.